Trends in long-term outcomes of patients with HCV-associated hepatocellular carcinoma after hepatectomy : A comparison before and after introduction of direct-acting antivirus therapy
© 2023 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery..
Backgrounds: The success of direct-acting antiviral (DAA) therapy provides a cure for patients chronically infected with hepatitis C virus (HCV); however, outcomes after hepatectomy for HCV-associated hepatocellular carcinoma (HCC) before and after DAA introduction remain poorly studied.
Methods: Patients who underwent R0/R1 hepatectomy for HCV-associated HCC were retrospectively analyzed. Two time periods were defined: Pre-DAA (2007-2011, December 2013 was defined as the end of follow-up) and Post-DAA groups (2014-2018, December 2020 was defined as the end of follow-up). Propensity score matching (PSM) analyses were performed to highlight the effect of DAA therapy.
Results: A total of 155 patients with HCV-associated HCC were included in this study (Pre-DAA group, n = 103 and post-DAA group, n = 52). In the Post-DAA group, DAA therapy was performed in 26 patients (50.0%), and all of these patients achieved sustained virologic response (SVR) (preoperative SVR, n = 7; postoperative SVR, n = 19). There was no significant difference between the two groups regarding surgical settings and tumor pathology. There was no significant difference in the 5-year overall survival (OS) rate (61.1% and 64.8%, pre- and post-DAA group, respectively, p = 0.441); meanwhile, the 5-year recurrence-free survival (RFS) rate in the post-DAA group was better than the pre-DAA group (21.1% and 40.2%, p = 0.073) with a trend toward significance. After PSM except for the postoperative SVR status, there were no significant differences in OS (p = 0.586) and RFS (p = 0.888).
Conclusions: This study showed that survival outcomes were not changed in hepatectomized cases of HCV-associated HCC before and after the introduction of DAA therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Annals of gastroenterological surgery - 8(2024), 1 vom: 10. Jan., Seite 133-142 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Munekage, Fumiaki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
DAA |
|---|
| Anmerkungen: |
Date Revised 23.01.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/ags3.12725 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367411741 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367411741 | ||
| 003 | DE-627 | ||
| 005 | 20240123232101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ags3.12725 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM367411741 | ||
| 035 | |a (NLM)38250678 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Munekage, Fumiaki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trends in long-term outcomes of patients with HCV-associated hepatocellular carcinoma after hepatectomy |b A comparison before and after introduction of direct-acting antivirus therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery. | ||
| 520 | |a Backgrounds: The success of direct-acting antiviral (DAA) therapy provides a cure for patients chronically infected with hepatitis C virus (HCV); however, outcomes after hepatectomy for HCV-associated hepatocellular carcinoma (HCC) before and after DAA introduction remain poorly studied | ||
| 520 | |a Methods: Patients who underwent R0/R1 hepatectomy for HCV-associated HCC were retrospectively analyzed. Two time periods were defined: Pre-DAA (2007-2011, December 2013 was defined as the end of follow-up) and Post-DAA groups (2014-2018, December 2020 was defined as the end of follow-up). Propensity score matching (PSM) analyses were performed to highlight the effect of DAA therapy | ||
| 520 | |a Results: A total of 155 patients with HCV-associated HCC were included in this study (Pre-DAA group, n = 103 and post-DAA group, n = 52). In the Post-DAA group, DAA therapy was performed in 26 patients (50.0%), and all of these patients achieved sustained virologic response (SVR) (preoperative SVR, n = 7; postoperative SVR, n = 19). There was no significant difference between the two groups regarding surgical settings and tumor pathology. There was no significant difference in the 5-year overall survival (OS) rate (61.1% and 64.8%, pre- and post-DAA group, respectively, p = 0.441); meanwhile, the 5-year recurrence-free survival (RFS) rate in the post-DAA group was better than the pre-DAA group (21.1% and 40.2%, p = 0.073) with a trend toward significance. After PSM except for the postoperative SVR status, there were no significant differences in OS (p = 0.586) and RFS (p = 0.888) | ||
| 520 | |a Conclusions: This study showed that survival outcomes were not changed in hepatectomized cases of HCV-associated HCC before and after the introduction of DAA therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DAA | |
| 650 | 4 | |a HCC | |
| 650 | 4 | |a HCV | |
| 650 | 4 | |a direct‐acting antivirals | |
| 650 | 4 | |a hepatectomy | |
| 650 | 4 | |a hepatitis C virus | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Yoh, Tomoaki |e verfasserin |4 aut | |
| 700 | 1 | |a Ogiso, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Takuya |e verfasserin |4 aut | |
| 700 | 1 | |a Nam, Nguyen Hai |e verfasserin |4 aut | |
| 700 | 1 | |a Nagai, Kazuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Uchida, Yoichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Ishii, Takamichi |e verfasserin |4 aut | |
| 700 | 1 | |a Hatano, Etsuro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of gastroenterological surgery |d 2017 |g 8(2024), 1 vom: 10. Jan., Seite 133-142 |w (DE-627)NLM285082434 |x 2475-0328 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:1 |g day:10 |g month:01 |g pages:133-142 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ags3.12725 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 1 |b 10 |c 01 |h 133-142 | ||